Top tier journal of research results published by Zhongshan Hospital, neoadjuvant therapy for esophageal cancer can significantly improve the survival of advanced patients with adjuvant therapy | Patients | Zhongshan Hospital

Release time:Apr 14, 2024 08:49 AM

Today, it was reported that Professor Tan Lijie and Professor Yin Jun from the Department of Thoracic Surgery of Fudan University Affiliated Zhongshan Hospital, in collaboration with BGI Gene Research, have found that the use of PD-L1 antibody immunotherapy combined with surgery is expected to improve the treatment effect of locally advanced esophageal cancer patients. The study is the first to reveal the biological characteristics of immunotherapy sensitive populations, opening up new avenues for treatment in related fields in China. The top tier journal of the achievement journal Nature Medicine.

It is reported that esophageal cancer is one of the top ten high-risk cancers in China, with over 90% of patients suffering from esophageal squamous cell carcinoma. Excessive consumption of tobacco and alcohol, as well as long-term hot drinking and eating, can increase the risk of illness. Due to the insidious symptoms, most patients are diagnosed in the middle and late stages, with a 5-year survival rate of only 20% to 30%. The surgical effect of esophageal cancer is poor, and comprehensive treatment such as surgery combined with radiotherapy, chemotherapy, and immunotherapy is the standard treatment method for locally advanced patients.

Since 2019, Professor Tan Lijie and Professor Yin Jun's team have collaborated with the Institute of Life Sciences at Huada University to jointly carry out the Phase Ib "NATION-1907" study on the use of self-developed PD-L1 monoclonal antibody - Adebelimumab - for neoadjuvant treatment of locally advanced resectable esophageal squamous cell carcinoma by Hengrui Pharmaceuticals. The so-called "neoadjuvant therapy" refers to the advancement of postoperative adjuvant therapy to preoperative stage, "downgrading" of locally advanced tumors, in order to obtain more possibilities for radical resection. Through effective neoadjuvant therapy, possible micro metastatic lesions in the body can also be eliminated in order to achieve long-term survival.


Top tier journal of research results published by Zhongshan Hospital, neoadjuvant therapy for esophageal cancer can significantly improve the survival of advanced patients with adjuvant therapy | Patients | Zhongshan Hospital

Expert introduction: Although the new adjuvant chemotherapy and radiotherapy recommended by the current guidelines can partially achieve the above goals, they have significant toxic side effects and limited beneficiaries. Finding an "efficient and low toxicity" model that can accurately implement tumors with different biological characteristics has always been an urgent problem to be solved.

30 patients were enrolled in the "NATION-1907" study, of which 25 completed neoadjuvant therapy and esophageal cancer radical surgery. Compared with historical controls of radiotherapy, chemotherapy or chemotherapy patients, the study showed significant survival benefits, overall safety was controllable, and no adverse reactions with significant or worsening symptoms occurred, nor did it lead to surgical delays or increased complications. The common side effects such as hair loss, vomiting, loss of appetite, and other systemic side effects during radiotherapy and chemotherapy have been effectively alleviated. Further data shows that patients who receive neoadjuvant immunotherapy have a two-year postoperative survival rate of over 90%, far exceeding the research design expectations. Research has confirmed that neoadjuvant immunotherapy has broad application prospects in locally advanced resectable esophageal squamous cell carcinoma. The study also revealed for the first time the biological characteristics of immunotherapy sensitive populations, providing important evidence for precision treatment.

As a pilot hospital for high-quality development of public hospitals and one of the first batch of comprehensive national medical centers, Zhongshan Hospital has been exploring deep integration with domestic medical innovation enterprises for a long time, establishing a "medical research and production" innovation cycle system. Fan Jia, academician of the CAS Member and president of Zhongshan Hospital, said that the cooperation between the clinical team and BGI is also evidence. At present, Zhongshan Hospital focuses on four directions: diagnosis and treatment technology, innovative drugs, medical equipment, and medical equipment, and has sorted out multiple "bottleneck" and "one stop at the door" research projects. It has signed contracts with more than 100 enterprises and platforms, and through medical and industrial cooperation, continues to promote the transformation of high-level basic medical research and clinical research results, helping innovative achievements "bloom in multiple places".


Top tier journal of research results published by Zhongshan Hospital, neoadjuvant therapy for esophageal cancer can significantly improve the survival of advanced patients with adjuvant therapy | Patients | Zhongshan Hospital
Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer
Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer

Immunotherapy has been proven to achieve significant therapeutic effects in various solid tumors. However, for pancreatic cancer, known as the "king of cancer", immunotherapy has been ineffective. On August 4, Professor Yu Xianjun, Dean of the Cancer Hospital Affiliated to Fudan University, and Shi Si, Associate Professor of Pancreatic Surgery released a research achievement, which first found the key role of cysteine rich protein 1 in shaping the immunosuppressive microenvironment of pancreatic cancer, filled the gap in the research field of immunosuppressive microenvironment of pancreatic cancer, and provided a theoretical basis for precise immunotherapy of pancreatic cancer patients. Ductal adenocarcinoma of the pancreas is the main type of pancreatic cancer, accounting for about 90% of all pancreatic cancer. Due to its high malignancy and poor treatment effectiveness, pancreatic ductal adenocarcinoma has always been one of the most malignant tumors. In recent years, the level of surgical techniques and comprehensive treatment has been achieved

A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare
A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare

A 14-year-old girl has been experiencing symptoms such as protruding pupils, incomplete eye closure, corneal injury, restricted eye movement, and overall fatigue for several years. The physical discomfort and facial abnormalities caused by eye diseases have made her increasingly reticent, and her temperament is vastly different from before. At the Ophthalmology Department of the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the pupil has been diagnosed with a rare thyroid ophthalmopathy combined with myasthenia gravis, which requires prompt treatment. However, considering the young age of the pupil, conventional hormone and radiation therapy cannot be used. Therefore, Zhou Huifang, Deputy Director of Ophthalmology and thyroid ophthalmology expert, has developed a targeted drug combined with surgical treatment plan for it, and targeted drug treatment will be performed first. Three months ago, I was hospitalized for one week with mydriasis and received intravenous targeted drug treatment. Afterwards, I went home for observation and followed up on time

The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease
The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease

According to the Statistics of Chinese Dry Eye Expert Consensus, the incidence rate of dry eye in China is about 21%~30%, and it is estimated that there are at least 300 million patients nationwide. The Dry Eye Diagnosis and Treatment Studio of Shanghai Eye Disease Prevention and Treatment Center was officially launched today. In the future, the studio will continuously improve the dry eye diagnosis and treatment standards, and form standardized diagnosis and treatment concepts and service models. Suitable technologies will be promoted to the community, allowing residents to enjoy convenient dry eye diagnosis and treatment services at their doorstep. Executive Dean and Party Secretary Gao Wei stated that this is also one of the livelihood service measures recently launched by the hospital around high-quality development and meeting the needs of the people. It is reported that dry eye syndrome is a chronic ocular surface disease caused by multiple factors. The instability of the tear film or imbalance of the ocular surface microenvironment caused by abnormal quality, quantity, and dynamics of tears can be accompanied by ocular surface inflammatory reactions, tissue damage, and nerve abnormalities, resulting in various discomforts in the eyes

The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice
The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice

The International Dental Implant Consensus Report, jointly written by the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine and renowned universities in the field of dentistry such as Harvard University, University of Zurich, University of Gothenburg, Columbia University, and University of Frankfurt, has recently been jointly published in top journals in the field of dentistry, including Clinical Periodontology and Clinical Dental Implant Research. This consensus has for the first time established an internationally unified core set of indicators for evaluating the clinical effectiveness of dental implants, covering the five key areas of the field of dental implants. It is of milestone significance for carrying out standardized clinical diagnosis, treatment, and research on dental implants. The core evaluation indicators determined by this consensus will become an important benchmark for scholars in the field of dental implants worldwide to conduct high-quality research. The consensus is composed of 8 top international experts in the field of oral implantation

Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases
Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases

Recently, Catherine, a British girl born in the 1990s, received autologous peripheral blood hematopoietic stem cell transfusion at the Cancer Center of Shanghai Jiahui International Hospital, and was successfully discharged from the warehouse. She is now on her way back to China after being discharged from the hospital. She is also the first patient at Shanghai Jiahui International Hospital to complete relevant treatments. In 2019, Catherine was diagnosed with Hodgkin's lymphoma in the UK, and after treatment, the disease completely improved. During her work and life in China in 2021, she went to seek medical attention due to multiple enlarged lymph nodes. Pathological biopsy confirmed a recurrence of Hodgkin's lymphoma, and through combined targeted drug treatment, her condition was temporarily under control. Last year in the second half of the year, when the disease recurred, the girl began to use immunotherapy combined with targeted drugs for treatment. Expert evaluation suggests that for young patients with hematological tumors, the risk of recurrence is high and treatment difficulty is increasing in the future. Autologous hematopoietic stem cell therapy is recommended